endo-dose-escalation

Guides dose escalation for obesity pharmacotherapy based on efficacy and tolerability while staying within approved upper dose limits. Triggers include clinician questions like "How should I titrate n

SKILL.md

GitHub

Guide dose escalation based on efficacy/tolerability

STEP 1 — Gather Information

Collect current medication, dose, duration, weight change (% body weight), adverse effects, comorbidities, concomitant medications, baseline weight, and patient goals. Action: Determine if the patient has tolerated the current dose and whether weight loss is below the efficacy threshold for that agent.

STEP 2 — Rule In / Rule Out

Is the patient tolerating the current dose (no severe or persistent side effects) AND has suboptimal response (weight loss <3% at 12 weeks for phentermine/topiramate, <5% at 12 weeks for naltrexone/bupropion or liraglutide, or <2% at 12 weeks for orlistat/lorcaserin)?

  • Yes: Proceed to dose escalation.
  • No: Maintain current dose if tolerable and partially effective, reduce dose if intolerable, or discontinue if ineffective and not tolerable.

STEP 3 — Classify or Stratify

Identify the specific obesity medication to select the appropriate dose-escalation schedule:

Medication Starting dose Step 1 Step 2 Step 3 (max)
Phentermine/topiramate ER 3.75/23 mg QD 7.5/46 mg QD 11.25/69 mg QD 15/92 mg QD
Naltrexone/bupropion 1 tablet QAM 1 tablet BID (weeks 2‑3) 2 tablets QAM + 1 tablet QPM (week 4) 2 tablets BID
Liraglutide 0.6 mg SC QD +0.6 mg weekly → 1.2 mg → 1.8 mg → 2.4 mg
Lorcaserin 10 mg QD 10 mg BID (max) — —
Orlistat 60 mg TID (OTC) 120 mg TID (prescription) — —
Action: Select the next dose level in the schedule based on current dose and tolerance.

STEP 4 — Decide

If the next dose level is within the upper approved limit and the patient remains tolerant, prescribe the escalated dose and schedule follow‑up in 4 weeks to reassess tolerance and weight change. If the patient is already at the maximum approved dose, maintain that dose and evaluate need for alternative therapy.

Clinical Guardrails / Mimics / Pitfalls

Do not exceed the upper approved dose for any agent; avoid escalation if emergent or worsening side effects (e.g., hypertension, tachycardia, mood changes, GI intolerance); do not escalate in pregnancy, uncontrolled hypertension, or recent MAOI use; monitor weight and adverse effects monthly; consider discontinuation if no ≥5% weight loss at max dose after 12 weeks.

Concrete Clinical Example

A 45‑year‑old woman with BMI 34 starts naltrexone/bupropion 8 mg/90 mg (1 tablet) each morning. After 4 weeks she reports mild nausea that resolved, and has lost 2% of body weight. Since she tolerates the dose and weight loss is <5%, the dose is escalated to 1 tablet BID (morning and evening). After another 4 weeks she tolerates the regimen and loses an additional 3%; dose is then increased to 2 tablets QAM + 1 tablet QPM, then to 2 tablets BID as tolerated.

Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415

TODO: consider adding scripts/calc.py for the endo-dose-escalation calculator